Ian Tomlinson, senior vice president and head of biopharmaceutical R&D at GlaxoSmithKline Plc, has joined the board of the UK’s first open innovation bioscience centre, Stevenage Bioscience Catalyst. The centre is a joint venture among GSK, the UK Department of Business, Innovation & Skills, the Wellcome Trust, the East of England Development Agency and the Technology Strategy Board. It will start operations in the first quarter of 2012. Mr Tomlinson will represent GSK’s interest in the project. As a senior GSK executive, he sits on GSK’s R&D executive committee.
Copyright 2011 Evernow Publishing Ltd